All articles by William Newton

William Newton is a Senior Reporter for Clinical Trials Arena and Pharmaceutical Technology, focusing on clinical trial design, healthcare business and regulation, and new technologies. Now based in New York City, he previously covered diabetes drug development at Close Concerns’ industry-facing publication in San Francisco. William holds a BA in Economics from Williams College.

William Newton


Successive AdCom wins for bluebird bio cue encouraging signs for rare disease gene therapies

It’s been a turbulent year for gene therapies targeting rare diseases. Could two recent votes for bluebird bio signal a change in fortune?

Can Relmada’s fast-acting pill for major depressive disorder compete in a crowded market?

Relmada’s investigational pill for major depressive disorder (MDD) could face tough competition with entrenched generic SSRIs and novices like J&J’s Spravato.

An oral pill for alcohol abuse vies to enter a quickly evolving market

Adial Pharmaceuticals CEO William Stilley discusses the challenges of bringing an alcohol abuse disorder therapy to market.

An uphill battle for insulin pricing reform as copay cap bill enters US Senate

Congress has renewed its longstanding push for insulin pricing reform with the Affordable Insulin Now Act, but will it be enough?

Insulin pricing: could an e-commerce approach cut costs?

An e-commerce drug delivery approach could put a dent in upward spiraling insulin prices, but uptake challenges loom large.

Amylyx AdCom: panelists narrowly vote against FDA approval in ALS despite strong patient advocacy

Some FDA panelists cited concerns with the ALS trial design, while others pointed to positive data and the high unmet need in ALS.

Navigating distribution challenges for rare disease drugs

On Rare Disease Day, Pharmaceutical Technology explores how specialty pharmacies and value-based contracts could shape drug distribution.

Mapping Endpoints: How to build an ALS clinical trial

Differing endpoint and efficacy expectations can make designing an ALS clinical trial challenging. Clinical Trials Arena looks at ways to dampen drug development obstacles.

Narrow FDA panel vote on Merck’s molnupiravir bolsters outlook on mAbs

A close FDA committee vote to authorize molnupiravir indicates that mAbs could still be favored for Covid-19 when available.

Schizophrenia drug landscape: a stagnant field on the cusp of change?

Several pipeline therapies could shake up the schizophrenia field, but their road through development is unlikely to be an easy path.